Phase 1 clinical trial of autologous dendritic cells to induce antigen-specific tolerance [ 2004 - 2004 ]

Research Grant

Researchers: Prof Ranjeny Thomas (Principal investigator) ,  Dr Paul Kubler

Brief description We have previously generated modified dendritic cells in mice with the ability to suppress immune responses once they have started. This project will develop the dendritic cell vaccine as a platform technology for human clinical use. We aim to demonstrate, in a phase I clinical trial, the capacity of modified human autologous dendritic cells to suppress the immune response to a model antigen in a group of healthy volunteers and a group of patients with rheumatoid arthritis taking drugs for their disease

Funding Amount $AUD 165,125.00

Funding Scheme NHMRC Development Grants

Notes Development Grant